Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned a consensus recommendation of “Buy” from the fourteen ratings firms that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $77.29.

A number of equities analysts recently commented on AGIO shares. BidaskClub lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 1st. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 8th. Janney Montgomery Scott lowered Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 26th. Finally, Cann reissued a “buy” rating and set a $75.00 price target on shares of Agios Pharmaceuticals in a research note on Sunday, June 11th.

In other news, Director Lewis Clayton Jr. Cantley sold 2,000 shares of the stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $50.87, for a total value of $101,740.00. Following the sale, the director now directly owns 90,197 shares in the company, valued at $4,588,321.39. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO David P. Schenkein sold 3,000 shares of the stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $50.02, for a total value of $150,060.00. Following the completion of the sale, the chief executive officer now owns 1,100 shares in the company, valued at $55,022. The disclosure for this sale can be found here. Over the last quarter, insiders sold 79,120 shares of company stock worth $4,557,207. Company insiders own 10.55% of the company’s stock.

Several large investors have recently modified their holdings of AGIO. Public Employees Retirement System of Ohio increased its stake in shares of Agios Pharmaceuticals by 52.8% in the second quarter. Public Employees Retirement System of Ohio now owns 18,353 shares of the biopharmaceutical company’s stock valued at $944,000 after buying an additional 6,338 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Agios Pharmaceuticals by 20.7% in the second quarter. California State Teachers Retirement System now owns 74,157 shares of the biopharmaceutical company’s stock valued at $3,816,000 after buying an additional 12,716 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,123 shares during the last quarter. State Street Corp increased its stake in shares of Agios Pharmaceuticals by 8.1% in the second quarter. State Street Corp now owns 1,302,966 shares of the biopharmaceutical company’s stock valued at $67,036,000 after buying an additional 97,220 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in shares of Agios Pharmaceuticals during the second quarter valued at $20,423,000. Hedge funds and other institutional investors own 83.13% of the company’s stock.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded up 1.64% during trading on Friday, hitting $55.79. The company had a trading volume of 191,296 shares. Agios Pharmaceuticals has a 52 week low of $35.84 and a 52 week high of $67.74. The firm’s 50 day moving average is $57.17 and its 200-day moving average is $52.32. The stock’s market capitalization is $2.70 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by $0.21. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The firm had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. During the same period in the previous year, the company posted ($1.47) earnings per share. Agios Pharmaceuticals’s quarterly revenue was up 62.1% on a year-over-year basis. Equities research analysts anticipate that Agios Pharmaceuticals will post ($7.07) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/18/agios-pharmaceuticals-inc-agio-given-consensus-recommendation-of-buy-by-brokerages.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.